Fig 2.

Relative (top) and absolute (bottom) errors during validation of CystiAgent against results from the Ring Strategy Trial for human taeniasis (left) and porcine cysticercosis (right) at baseline (month 0) and trial-end (month 24) (n = 21 villages). For ring treatment (n = 6 villages), ring screening (n = 8 villages) and mass treatment (n = 7 villages villages), interventions with (white) and without (grey) pig treatment are designated by the background color of the plot area. Three villages (570, 578, and 585) had no human taeniasis identified at trial-end and relative errors were not able to be calculated.